Close Menu

Precision Oncology News: Breaking News

Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.  

The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.

Assessing T cell fraction alongside tumor thickness was superior to other histopathological variables for accurate progression-free survival prediction.

BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.

AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.

Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.

National Institute for Health and Care Excellence draft guidance suggests more data is needed before using larotrectinib to treat UK cancer cases in histology-independent setting.

Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.

Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.

The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.

Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.

Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.

The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.

The finding suggests that African-American patients may be more likely to respond to treatment with poly ADP ribose polymerase (PARP) inhibitors.

In NSCLC driven by MET exon 14 alterations, research indicates Xalkori had some activity.

The worldwide license provides Iovance Biotherapeutics exclusive rights to Cellectis' TALEN gene editing technology for multiple gene targets to modify TILs for treating various cancers.

The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.

In the trial that led to Ayvakit's approval, 84 percent of patients with PDGFRA exon 18 mutations saw their tumors shrink.

Acepodia's off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

The company will submit the data as part of a new drug application for pralsetinib for RET fusion-positive non-small cell lung cancer.

Pages